STERIS plc

STERIS plc announced it will host a conference call to discuss its fiscal 2027 first quarter results on August 6, 2026, at 9:00 a.m. ET. A press release detailing the financial results will be issued after the U.S. market closes on August 5, 2026. A replay of the call will be available starting August 6, 2026, at 12:00 p.m. ET.

STERIS plc has filed its Definitive Proxy Statement (DEF 14A) for its 2026 Annual General Meeting (AGM) of Shareholders, scheduled for July 31, 2026, in Dublin, Ireland. The meeting will cover the election of nine directors, ratification of its independent registered public accounting firm, appointment and remuneration of its Irish statutory auditor, an advisory vote on executive compensation, and the renewal of the Board's authority to issue shares and opt-out of pre-emption rights under Irish law. The Board unanimously recommends a 'FOR' vote on proposals 1 through 7.

STERIS plc filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, detailing its operations across three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, following the fiscal 2025 divestiture of its Dental segment. The company reported an increase in capital equipment backlog to $490.7 million at year-end, driven by shipment timing and acquisitions. The report also highlighted STERIS's commitment to ethical business practices, environmental conservation, and human capital management, including improved safety metrics and a diverse global workforce.

STERIS plc announced strong financial results for its fiscal 2026 fourth quarter and full year ended March 31, 2026. Full year revenue from continuing operations increased 9% to $5.9 billion, with adjusted diluted EPS rising to $10.17. The company also reported a 7% increase in fourth-quarter revenue to $1.6 billion and a significant increase in free cash flow. Additionally, STERIS's Board of Directors authorized a new $1 billion share repurchase program, replacing the prior authorization.

STERIS plc announced strong financial results for its fiscal 2026 fourth quarter and full year ended March 31, 2026, marking another record year. Full year revenue from continuing operations increased 9% to $5.9 billion, with adjusted diluted EPS rising to $10.17. The company's Board of Directors also approved a new $1 billion share repurchase program. Looking ahead, STERIS anticipates fiscal 2027 revenue to increase 7-8% and adjusted diluted EPS to be in the range of $11.10 to $11.30.

STERIS plc announced changes to its Board of Directors. Richard C. Breeden will retire and not seek re-election after 18 years of service. Concurrently, the Board increased its size from nine to ten members and appointed Pierre Boulud as a new director, effective May 5, 2026. Mr. Boulud, currently the CEO of bioMérieux, brings extensive leadership and operational experience from the biotechnology and pharmaceutical sectors.

STERIS plc announced the appointment of Pierre Boulud to its Board of Directors, effective May 5, 2026. Mohsen Sohi, Chairman of STERIS, highlighted Boulud's leadership experience, global perspective, strategic acumen, and operational expertise as valuable additions. Boulud currently serves as CEO of bioMérieux and previously held significant roles at Ipsen and The Boston Consulting Group.

STERIS plc announced a quarterly dividend of $0.63 per share. The dividend is scheduled for payment on June 26, 2026, to shareholders who are on record as of the close of business on June 8, 2026. Additional information regarding the U.S. tax treatment of dividends is available on the company's investor relations website.

STERIS plc announced it will host a conference call on May 12, 2026, at 9:00 a.m. ET to discuss its fiscal 2026 fourth quarter and full year financial results. A press release detailing these results will be issued after the U.S. market closes on May 11, 2026. Investors can access the live call via webcast or phone, with a replay available afterward.

STERIS plc amended its Transition Agreement with former CFO Michael J. Tokich, extending his employment as a senior financial advisor on a part-time basis through March 31, 2027. The amendment reduces his annual base salary to $60,000 and eliminates benefits, while maintaining eligibility for a discretionary cash bonus, providing insight into the company's ongoing financial advisory structure.